UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Statement of Cash Flows
Net income	$ 7,938	$ 7,910
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	459	494
Amortization	1,913	1,957
(Gain) loss on investments	0	0
Provision for (recovery of) losses on accounts receivable	5	10
Deferred income taxes	(567)	(613)
(Gain)/Loss on disposal of assets	6
Stock-based compensation expense	21	54
Changes in operating assets and liabilities:
Accounts receivable - trade	(489)	(140)
Accrued interest and other receivables	(170)	(111)
Inventories	(205)	336
Prepaid expenses and other current assets	19	(88)
Accounts payable	226	232
Accrued expenses	315	531
Deferred revenue	(75)	(75)
Other liability	(339)	0
Total adjustments	1,120	2,588
Net cash provided by operating activities	9,058	10,499
Capital expenditures for property and equipment	(222)	(195)
Capital expenditures for intangible assets	(5)	(1)
Purchases of investments
Proceeds from sale of investments
Net cash (used in) provided by investing activities	(227)	(197)
Proceeds from issuance of common stock - options	647	1,185
Common stock purchased and retired	0	0
Payment of taxes for exchange of stock options	(90)	0
Tax benefit attributable to exercise of stock options	241	99
Repayment of notes payable	(2,909)	(7,174)
Payment of dividends	(1,824)	(1,762)
Net cash (used in) provided by financing activities	(3,935)	(7,652)
Effect of exchange rate changes on cash	103	103
NET INCREASE IN CASH	4,999	2,754
CASH AT BEGINNING OF PERIOD	8,871	6,534
CASH AT END OF PERIOD	13,870	9,288
Cash paid during the period for income taxes	2,662	2,621
Cash paid during the period for interest	$ 341	$ 516